To test this hypothesis, we chose as a model system prostate cancer because hyperactivation of the PI3K-AKT-mTOR pathway has been associated with disease progression from the primary to metastatic phase and carboxymethyl sensitive PP2A regulatory subunits regulates this pathway24,37,38. The gene discussed is MTOR; the disease is prostate carcinoma.